465 studies found for:    "Squamous cell carcinoma of the head and neck"
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Recruiting A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Conditions: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (RM HNSCC) Patients Who Are Resistant or Ineligible/Intolerant to Platinum-based Chemotherapy.;   Recurrent Head and Neck Squamous Cell Carcinoma;   Metastatic Head and Neck Squamous Cell Carcinoma
Interventions: Drug: BYL719+cetuximab;   Biological: cetuximab
2 Unknown  Study of 3-Dimensional Conformal Radiotherapy (3D-CRT) Versus Intensity Modulated Radiotherapy (IMRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Radiation: 3 Dimensional Radiation Therapy;   Radiation: Intensity Modulated Radiation Therapy
3 Terminated EMD 1201081 + 5-FU + Cisplatin + Cetuximab in Subjects With Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Drug: EMD 1201081 + 5-FU + Cisplatin + Cetuximab
4 Completed A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
Conditions: HER2 + Breast Cancer, HER2 + Gastric Cancer, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma;   HER2 + Breast Cancer;   HER2 + Gastric Cancer;   Squamous Cell Carcinoma of Head and Neck;   Esophageal Squamous Cell Carcinoma
Intervention: Drug: LJM716
5 Active, not recruiting E7050 in Combination With Cetuximab Versus Cetuximab Alone in the Treatment of Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Condition: Platinum-Resistant Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: E7050;   Drug: Cetuximab
6 Active, not recruiting A Trial Exploring the Efficacy of EMD 1201081 in Combination With Cetuximab in Second-Line Cetuximab-Naïve Subjects With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Condition: Squamous Cell Carcinoma of the Head and Neck Cancer
Interventions: Drug: Cetuximab in combination with EMD 1201081;   Drug: Cetuximab alone
7 Active, not recruiting Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Dalantercept
8 Recruiting Re-irradiation With Fractionated Stereotactic Radiosurgery Plus Cetuximab in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Cetuximab and stereotactic radiosurgery
9 Unknown  Erlotinib, Radiation Therapy and Cisplatin in Patients With Complete Resected Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Erlotinib clorhidrate;   Drug: Cisplatin;   Procedure: Radiation therapy
10 Recruiting Study of Dacomitinib With Radiotherapy With and Without Cisplatin in Patients With Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Dacomitinib;   Radiation: Radiotherapy;   Drug: Cisplatin
11 Terminated Combination of Cisplatin, Cetuximab and Temsirolimus in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: temsirolimus;   Drug: cisplatin;   Drug: cetuximab
12 Unknown  Combined FDG PET/CT Imaging in Response Evaluation After Radiochemotherapy in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Locally Advanced Squamous Cell Carcinoma of the Head and Neck Region
Intervention: Other: Integrated FDG PET/CT
13 Recruiting Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Other: Plasma samples
14 Unknown  MAGE-A3/HPV 16 Vaccine for Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Biological: MAGE-A3;   Biological: HPV-16 vaccine
15 Recruiting Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cabazitaxel;   Drug: Methotrexate
16 Recruiting Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Pazopanib;   Drug: Cetuximab
17 Recruiting A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Afatinib;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Cisplatin;   Radiation: Intensity Modulated Radiation Therapy
18 Active, not recruiting
Has Results
Cetuximab With Radiotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck in Chinese Subjects
Condition: Squamous Cell Carcinoma of the Head and Neck
Intervention: Biological: Cetuximab + concomitant boost radiotherapy
19 Completed
Has Results
Study of Cetuximab in Combination With Chemotherapy in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Drug: Cisplatin/Carboplatin;   Drug: 5-Fluorouracil
20 Recruiting ERBITUX® Followed by Adjuvant Treatment With Chemoradiation and ERBITUX® for Locally Advanced Head and Neck Squamous Cell Carcinoma
Condition: Squamous Cell Carcinoma of the Head and Neck
Interventions: Drug: Cetuximab;   Procedure: Surgery;   Radiation: Post-surgical radiation;   Drug: Cisplatin or carboplatin

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years